Loading…
Praxis Precision Medicines, Inc. is projected to rise to $379.04 by 2027, a +23% move from its current price of $307.75. PRAX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $298.00 | $307.99 | $318.30 | +0.08% |
| Aug 2 | $294.19 | $308.22 | $322.92 | +0.15% |
| Aug 3 | $291.34 | $308.46 | $326.57 | +0.23% |
| Aug 4 | $289.00 | $308.69 | $329.72 | +0.31% |
| Aug 5 | $286.98 | $308.93 | $332.55 | +0.38% |
| Aug 6 | $285.19 | $309.16 | $335.15 | +0.46% |
| Aug 7 | $283.57 | $309.40 | $337.58 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $283.57 | $309.40 | $337.58 | +0.54% |
| Week 2 | $274.97 | $311.06 | $351.87 | +1.07% |
| Week 3 | $268.89 | $312.72 | $363.70 | +1.62% |
| Week 4 | $264.09 | $314.40 | $374.29 | +2.16% |
| Week 5 | $260.10 | $316.08 | $384.12 | +2.71% |
| Week 6 | $256.67 | $317.78 | $393.43 | +3.26% |
| Week 7 | $253.67 | $319.48 | $402.37 | +3.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Praxis Precision Medicines, Inc. (PRAX) is a clinical-stage biopharmaceutical company focused on therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Its platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE.
In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc.
and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Praxis Precision Medicines, Inc. (PRAX) is a clinical-stage biopharmaceutical company focused on CNS disorders characterized by neuronal excitation-inhibition imbalance. The stock trades at $304.43 per share with a market capitalization of $8.49B and ranks 951 by market cap.
The current price and forecast imply an evolving price trajectory with meaningful upside over the coming years. The 30-day technical picture shows a bullish tilt with defined support and resistance levels, underscoring a path of potential appreciation.
A major floor 25.6% below — a decisive break under it would weaken the trend.
The nearest floor, 12.3% below — buyers have tended to step in here.
The nearest ceiling, 13.9% above — a clean break opens room to run.
A major ceiling 26.7% above — clearing it would confirm fresh momentum.
Key PRAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $307.14 | Buy | $305.37 | Buy |
| MA 10 | $310.69 | Sell | $309.33 | Sell |
| MA 20 | $316.14 | Sell | $311.55 | Sell |
| MA 50 | $307.71 | Buy | $311.58 | Sell |
| MA 100 | $313.67 | Sell | $304.60 | Buy |
| MA 200 | $283.15 | Buy | $267.52 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.54 | Neutral |
| Stoch RSI (14) | 50.14 | Neutral |
| CCI (20) | -66.74 | Neutral |
| Williams %R (14) | -54.38 | Info |
| MACD (12,26,9) | -2.68 | Sell |
| ROC (12) | -6.08 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 45.62 | Neutral |
| TRIX (15) | 0.10 | Buy |
| Awesome (5,34) | -1.39 | Sell |
| Ultimate (7,14,28) | 44.80 | Neutral |
| Momentum (10) | -0.45 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 296.20 | Buy |
| ADX (14) | 10.01 | Neutral |
| ATR (14) | 10.13 | Info |
The near-term technical setup shows a bullish tilt. RSI14 is 50, with the 50-day simple moving average at $311.83 and the 200-day moving average at $272.85. Key near-term support sits at $240.66 and resistance at $350.56.
The 30-day price range spans from $244.90 to $378.43, highlighting active trading within a broad band. Annualized volatility is 60%, indicating substantial price movement potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $240.66 | $307.75 | $423.55 | 0% | Neutral | |
| $296.58 | $379.04 | $515.55 | +23% | Bullish | |
| $313.83 | $415.31 | $590.31 | +35% | Bullish | |
| $439.06 | $598.10 | $879.59 | +94% | Bullish | |
| $532.34 | $744.00 | $1,125.75 | +142% | Bullish | |
| $559.45 | $800.42 | $1,241.44 | +160% | Bullish | |
| $618.10 | $903.92 | $1,433.24 | +194% | Bullish | |
| $646.11 | $964.57 | $1,560.19 | +213% | Bullish | |
| $691.37 | $1,052.65 | $1,734.06 | +242% | Bullish | |
| $786.93 | $1,221.01 | $2,045.72 | +297% | Bullish | |
| $1,146.84 | $1,940.58 | $3,488.73 | +531% | Bullish | |
| $2,580.51 | $5,090.60 | $10,129.83 | +15.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $240.66 | $307.75 | $359.23 | +0.00% |
| August 2026 | $265.08 | $312.47 | $377.93 | +1.53% |
| September 2026 | $277.08 | $329.94 | $405.51 | +5.59% |
| October 2026 | $279.98 | $336.12 | $418.34 | +1.87% |
| November 2026 | $272.75 | $329.65 | $414.48 | -1.93% |
| December 2026 | $274.47 | $333.78 | $423.55 | +1.25% |
Click any year to see its month-by-month PRAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PRAX price prediction for 2026 points to an average of $307.75 (low $240.66, high $423.55) — a potential gain of 0% on today's $307.75. Price action looks broadly range-bound.
In 2027, PRAX is projected to trade between $296.58 and $515.55, averaging $379.04 — a potential gain of +23% from today's $307.75. That is up +23% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Praxis Precision Medicines, Inc.'s 2028 outlook centres on $415.31, within a $313.83 to $590.31 range. That is up +10% on the projected 2027 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2029, PRAX could reach as high as $879.59, with a base case around $598.10 and support toward $439.06 — roughly +94% from $307.75. Buyers look set to stay in control over this stretch.
Expect PRAX to range from $532.34 to $1,125.75 through 2030. The $744.00 average target implies a +142% move from current prices. That is up +24% on the projected 2029 average. Momentum favours further upside here.
The PRAX price prediction for 2031 points to an average of $800.42 (low $559.45, high $1,241.44) — a potential gain of +160% on today's $307.75. Buyers look set to stay in control over this stretch.
In 2032, PRAX is projected to trade between $618.10 and $1,433.24, averaging $903.92 — a potential gain of +194% from today's $307.75. That is up +13% on the projected 2031 average. Momentum favours further upside here.
Praxis Precision Medicines, Inc.'s 2033 outlook centres on $964.57, within a $646.11 to $1,560.19 range. That is up +7% on the projected 2032 average. That marks a +213% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, PRAX could reach as high as $1,734.06, with a base case around $1,052.65 and support toward $691.37 — roughly +242% from $307.75. Momentum favours further upside here.
Expect PRAX to range from $786.93 to $2,045.72 through 2035. The $1,221.01 average target implies a +297% move from current prices. That is up +16% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The PRAX price prediction for 2040 points to an average of $1,940.58 (low $1,146.84, high $3,488.73) — a potential gain of +531% on today's $307.75. Momentum favours further upside here.
In 2050, PRAX is projected to trade between $2,580.51 and $10,129.83, averaging $5,090.60 — a potential gain of +15.5x from today's $307.75. That is up +162% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PRAX today (≈ 3.249391 PRAX) could be worth
$16,541.36
+$15,541.36 (+1554%) by 2050 · US Dollar
Based on the average projected PRAX price of $5,090.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRAXwould be worth at today's price.
$1,000 invested in PRAX on Jul 30, 2025 (≈ 17.670967 PRAX) would be worth
$5,438.24
+$4,438.24 (+443.8%) today · 5.44× · US Dollar
Based on a PRAX entry price of $56.59 vs. today's $307.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $322.4 | $954.56 | -4.5% |
| 1 month ago | $334.79 | $919.23 | -8.1% |
| 3 months ago | $324.2 | $949.26 | -5.1% |
| 6 months ago | $314 | $980.1 | -2.0% |
| 1 year ago | $56.59 | $5,438.24 | +443.8% |
| All time (5.0y) ago | $233.7 | $1,316.86 | +31.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRAX forecast.
Our base-case forecast reaches $620.00 around 2030.
Implied market cap at $620.00: $17.28B
Year-by-year forecasts show a strong multi-year upside for PRAX. The 2026 forecast is neutral with an average price of $304.43 and a ROI of 0%; sentiment NEUTRAL. The 2027 forecast has an average price of $370.54 with a ROI of 21.7% and a sentiment BULLISH.
The 2028 forecast shows an average price of $404.57 with a ROI of 32.9% and a sentiment BULLISH. The 2029 forecast shows an average price of $589.98 with a ROI of 93.8% and a sentiment BULLISH. The 2030 forecast shows an average price of $716.30 with a ROI of 135.3% and a sentiment BULLISH.
The 2031 forecast shows an average price of $763.34 with a ROI of 150.7% and a sentiment BULLISH. The 2032 forecast shows an average price of $881.22 with a ROI of 189.5% and a sentiment BULLISH. The 2033 forecast shows an average price of $919.16 with a ROI of 201.9% and a sentiment BULLISH.
The 2034 forecast shows an average price of $992.31 with a ROI of 226% and a sentiment BULLISH. The 2035 forecast shows an average price of $1,176.46 with a ROI of 286.4% and a sentiment BULLISH. The 2040 forecast shows an average price of $1,826.81 with a ROI of 500.1% and a sentiment BULLISH.
The 2050 forecast shows an average price of $4,762.51 with a ROI of 1464.4% and a sentiment BULLISH. These figures suggest sizable upside over the long horizon, though outcomes depend on development progress and market conditions.
Tap a question to reveal the answer.
The forecast shows an average price of $716.30 in 2030 with a maximum of $1,085.06 and a minimum of $511.99; the ROI is 135.3% and the sentiment is BULLISH.
Forecasts point to a bullish trend from 2027 onward, with rising averages (e.g., $370.54 in 2027, $716.30 in 2030) and meaningful upside by 2040 and 2050. These are estimates, not guarantees, and should be weighed with real-world risks.
Yes. The 2031–2033 period shows max prices of $1,185.20 (2031) and $1,488.27 (2033), with 2040 at a max of $3,287.34, indicating potential above $1,000 in the forecast window.
Current price is $304.43 and market cap is $8.49B; the stock is ranked 951.
The 30-day range is $244.90 to $378.43, RSI is 50, SMA50 is $311.83, SMA200 is $272.85, with support at $240.66 and resistance at $350.56; annualized volatility is 60%.
Praxis Precision Medicines, Inc. Community Discussion
0Share your Praxis Precision Medicines, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.